|Mr. Scott D. Myers||Pres, CEO & Director||744.57k||N/A||51|
|Ms. Julia M. Eastland M.B.A.||CFO, Chief Bus. Officer & Sec.||467.44k||N/A||53|
|Mr. Gary W. Christianson PE||Chief Operating Officer||443.02k||N/A||62|
|Dr. Scott Robert Peterson Ph.D.||Chief Scientific Officer||494.44k||N/A||55|
|Dr. Gwen A. Fyfe M.D.||Consultant & Director||48.9k||N/A||65|
Cascadian Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States. The company lead clinical-stage product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. It is also developing Checkpoint kinase 1, a protein kinase that is in pre-clinical studies to regulate the cell division cycle, as well as to DNA damage and replication stress. In addition, the company focuses on the development of novel antibodies and T-cell immunoreceptor with Ig and ITM domains, an inhibitory receptor expressed on T-cells and NK cells that negatively regulate immune response to cancers. It has a license agreement with Array BioPharma Inc. to develop, manufacture and commercialize tucatinib; research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; and collaboration agreement with Adimab LLC for the discovery of novel antibodies against d immunotherapy targets in oncology. The company was formerly known as Oncothyreon Inc. and changed its name to Cascadian Therapeutics, Inc. in June 2016. Cascadian Therapeutics, Inc. was founded in 1985 and is headquartered in Seattle, Washington.
Cascadian Therapeutics, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 7. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 7.